April 16, 2026 07:31 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘We are surprised’: SC stays Pawan Khera’s bail over remarks on Himanta Biswa Sarma’s wife | Historic shift: Bihar gets first BJP CM as Samrat Choudhary takes oath | 'ECI deviated from Bihar procedure': Supreme Court raises concerns over voter deletion in Bengal SIR | Noida workers’ protest turns violent: Stones pelted, vehicles damaged over wage hike demand | Oil prices jump above $103 a barrel as US moves to block Iran-linked shipping | I don’t care if they come back or not, says Trump after Iran talks collapse | Legendary singer Asha Bhosle suffers cardiac arrest, hospitalised | Big boost to India–Mauritius ties: S. Jaishankar hands over 90 e-buses | Middle East tension: Iranian delegation arrives in Islamabad for major talks, 10,000 security personnel deployed | Ranveer Singh visits RSS HQ amid Dhurandhar 2 success, triggers speculation
Sputnik V
UNSPLASH

AstraZeneca vaccine will work better, faster if 2nd dose replaced with Sputnik V:Makers

| @indiablooms | Feb 20, 2021, at 10:37 pm

Moscow/Sputnik: Developers of Russia's Sputnik V coronavirus vaccine said on Saturday that AstraZeneca can achieve maximum efficacy of its vaccine in less than a three-month interval if it uses Sputnik V as its second shot.

On Friday, The Lancet published a study in which AstraZeneca said that it found out that its vaccine works better if the two doses are administered three months, not three weeks apart.

"SputnikV team believes that AstraZeneca research … shows: 1. Immunity created by the first AZ shot prevents the second shot from being effective (overall efficacy of only 55%) unless there is a wait of 3 months. 2. Sputnik V solves this elegantly through heterogeneous boosting (using a different second shot). 3. Using Sputnik V shot as a second shot for AZ vaccine will eliminate the need to wait for 3 months," developers said on Twitter.

According to the statement, clinical trials of the AstraZeneca/Sputnik V combination vaccine have already started.

Sputnik V added that it has offered its second shot not only to AstraZeneca but also to "other vaccines with efficacy below 90%."

Sputnik V is a human adenoviral platform-based vaccine, which was developed by Russia's Gamaleya Center and registered by the Russian government on August 11 last year. Interim results from Phase 3 clinical trials established its efficacy at 91.6 percent, as published by The Lancet.

In December, Gamaleya and AstraZeneca signed a memorandum of understanding to test a combination of their vaccine components. AstraZeneca's chimpanzee adenovirus-based vaccine alone demonstrated significantly lower efficacy in clinical trials.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.